Global Markets: Novavax begins late-stage COVID-19 trials

By MarketsFarm

WINNIPEG, Sept. 25 (MarketsFarm) – The following is a glance at the news moving markets in Canada and globally.

United States-based drug company Novavax has begun late-stage trials of a potential COVID-19 vaccine in the United Kingdom. The trial involves 10,000 people ranging between 18 and 84. According to a statement issued on Thursday, at least 25 per cent of the subjects will be over the age of 65. The trial is conducted in partnership with the U.K. government’s Vaccine Taskforce.

Lockdowns are being imposed in several cities in the U.K. due to sharp rises in COVID-19 cases. About 750,000 people in northern England will not be allowed to mix with other households indoors or in backyards, though the city of London has not faced such restrictions yet. According to recent estimates, there were approximately 9,600 new infections per day in England last week, which was a 60 per cent increase from the week prior.

A new report from Bloomberg showed top Kremlin agents are “increasingly alarmed” by the prospect of Democratic nominee Joe Biden winning the U.S. presidential election in November. U.S. officials say Russia has already meddled in the election, conducting a “very active” campaign against Biden. Biden’s victory could cause the Kremlin to move up their parliamentary elections before a new administration could impose new sanctions or other penalties.

explore

Stories from our other publications